Brought to you by 
Acceleron and Celgene develop bone loss candidate
20 Sep 2017
Executive Summary
Acceleron Pharma (developing therapeutics that promote bone growth) and Celgene (cancer and inflammatory disease treatments) will together develop Acceleron's ACE011 bone-forming compound that is in Phase IIa clinical trials in cancer patients.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Acceleron and Celgene develop bone loss candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice